A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
HealthDay News — Benzodiazepine use in pregnancy is not associated with an increased risk for major congenital malformations, according to a study published online October 13 in the Annals of Internal ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
Strong recommendations made for semiannual surveillance for HCC, testing and vaccination for hepatitis A and B.
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms and preventing postmenopausal ...
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth ...
The newly approved autoinjector provides an alternative to the prefilled syringe for daily self-administration.
The FDA has granted over-the-counter approval to Brytly (apraclonidine ophthalmic solution 0.125%) for the symptomatic relief of eye redness due to minor irritation in individuals aged 12 years and ...
Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...
The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results